Rhythm Biosciences (ASX:RHY) share price jumps 12% on key milestone

The Rhythm Biosciences share price was on fire on Wednesday. Here's why…

| More on:
Lab worker puts hands in the air and dances around

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price was a very strong performer on Wednesday.

The predictive diagnostics company's shares ended the day 12% higher at $1.32.

This means the Rhythm Biosciences share price is now up 550% over the last 12 months.

Why did the Rhythm Biosciences share price surge higher today?

Investors were bidding the Rhythm Biosciences share price higher today following the release of a milestone announcement.

According to the release, the company has completed recruitment for its clinical trial (Study 7) for ColoSTAT.

ColoSTAT is a globally marketed, low-cost, simple blood test for the early detection of colorectal cancer aimed at mass-market screening.

The release explains that Rhythm Biosciences has now successfully recruited 815 patients across 11 Australian clinical trial sites. This was deemed to be an adequate number of patients following a detailed consultation with leading industry professionals and the company's biostatisticians and Clinical Research Organisation (CRO).

Management notes that the recruitment phase is a highly involved and resource intensive component of the clinical trial. Therefore, it feels the completion of this phase represents a significant milestone towards the final completion of the clinical trial study.

What's next?

The good news for the Rhythm Biosciences share price is that ColoSTAT could be generating revenue in the not so distant future.

The company will now commence testing the collected blood samples, finalise and lock the patient database, and other routine associated works. It will also progress the next stages in finalising the trial, before completing the final clinical study report.

If all goes to plan, the clinical trial is targeted for completion in the first half of calendar year 2022. After which, it is hoping for approval to market ColoSTAT within Australia later that year.

European trials are ongoing as well, with a filing expected to be made before the end of the year.

Management commentary

Rhythm's CEO, Glenn Gilbert, said: "With the recruitment target now met for the ColoSTAT clinical trial, the Company remains fully focused on working with our partners to progress through the remaining phases for trial completion."

"In the context of market conditions made extremely difficult by COVID-19, I am proud of the achievement by the entire Rhythm team, our trial sites, CRO, operations and laboratory partners. This milestone should not be understated, considering the recruitment phase is typically the most resource, logistically challenging and cost intensive component of completing a clinical trial," he added.

Management estimates that ColoSTAT has a $6.5 billion market opportunity across the US, European, and Australian markets.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Man pointing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Champion Iron, EBR Systems, Mesoblast, and Patriot Battery Metals shares are surging today

These shares are avoiding the market selloff on Thursday. But why?

Read more »

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors ended up snatching defeat from the jaws of victory today.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Share Gainers

Why Clarity, Omni Bridgeway, Santana Minerals, and Vulcan shares are pushing higher today

These shares are having a good time on hump day. But why?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 44%

Investors are sending the ASX All Ords stock racing higher today. But why?

Read more »

A young boy wearing a hat, sunnies and striped singlet looks fierce and flexes his arm in victory.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finally caught a break this Tuesday.

Read more »

three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
Share Gainers

Why Novonix, PEXA, Tamboran Resources, and Westgold shares are storming higher

These shares are having a good time on Tuesday. Let's find out what's happening.

Read more »

Silhouettes of nine people climbing a steep mountain to the top at sunset, and helping each other along the way.
Share Gainers

Here are the top 10 ASX 200 shares today

The markets endured a rough start to the week this Monday.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why 4DMedical, Brainchip, Meridian, and SCEE shares are rising today

These shares are having a strong start to the week. But why?

Read more »